Active Ingredient(s): Copper Dotatate Cu-64
FDA Approved: * September 3, 2020
Pharm Company: * RADIOMEDIX
Category: Diagnostic Aid

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Detectnet Overview

Copper (64Cu) oxodotreotide or Copper Cu 64 dotatate, sold under the brand name Detectnet, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults.[2] Common side effects include nausea, vomiting and flushing.[3] It was approved for medical use in the United States in September 2020.[2][3] Contents 1 His...

Read more Detectnet Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Detectnet Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Copper Dotatate Cu-64
  • Injection: 0.4mg/ml, 1.07mg/ml
  • Solution: 4ml (1mci/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Detectnet: (1 result)

Sorted by National Drug Code
  • 69945-064 Detectnet 1 mci/Ml Intravenous Injection, Solution by Curium Us LLC

Other drugs which contain Copper Dotatate Cu-64 or a similar ingredient: (1 result)